NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed on behalf of shareholders of Quantum Biopharma Ltd. ("Quantum" or the "Company") (NASDAQ: QNTM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
The class action concerns whether Quantum and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
You have until February 23, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Quantum securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.
A complaint has been filed alleging that CIBC World Markets, Inc., CIBC World Markets Corp., The Canadian Imperial Bank of Commerce, RBC Dominion Securities, Inc., RBC Capital Markets, LLC, and Royal Bank of Canada (collectively, the "Defendants") repeatedly entered thousands of spoofed sell orders designed to create the false impression in the market that Quantum's stock price was falling. These manipulative orders were calculated to (and successfully did) deceive or induce other investors to sell their holdings at artificially low prices. After driving the market price down, Defendants purchased shares at these artificially depressed levels and positioned themselves to profit. Meanwhile, other Quantum investors were baited into selling their shares at artificially depressed prices.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
View original content to download multimedia:https://www.prnewswire.com/news-releases/contact-investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-quantum-biopharma-ltd-of-class-action-lawsuit-and-upcoming-deadlines--qntm-302666583.html
SOURCE Pomerantz LLP
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
